Gland Pharma shareholders and shareholding pattern
NSE: GLANDBSE: 543245Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,960.30.
28 Oct: open ₹2,950.00, high ₹3,061.50, low ₹2,924.00
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹50,312 Cr261st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 44.57
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.66%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,82,54245.7% delivered
Gland Pharma's shareholding pattern for Sep 2026, filed on 16 Oct 2026, with every filing from Dec 2020: who owns its shares by group, its promoters by name and its public holders of 1% or more.
Who owns Gland Pharma, filing by filing
Per cent of the company's shares.
Sep 2026 filing
- Promoters45.75%
- Foreign institutions10.36%
- Indian institutions33.21%
- Governments0.01%
- Individuals and others10.66%
Shareholding pattern, per cent, from Sep 2022
- Promoters
- Foreign institutions
- Indian institutions
- Governments
- Individuals and others
| Per cent | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.36% | 58.25% | 58.14% | 58.02% | 58.00% | 58.00% | 57.87% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% | |
| Foreign promoters | 58.36% | 58.25% | 58.14% | 58.02% | 58.00% | 58.00% | 57.87% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% | 45.75% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. Public in the glossary | 41.64% | 41.75% | 41.86% | 41.97% | 42.00% | 42.00% | 42.13% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 42.14% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.17% | 48.23% | 54.25% |
| Shares in issue | 16,32,82,823 | 16,35,92,923 | 16,39,04,723 | 16,42,37,173 | 16,43,02,723 | 16,43,02,723 | 16,46,55,923 | 16,46,88,423 | 16,46,90,223 | 16,47,00,823 | 16,47,00,823 | 16,47,00,823 | 16,47,01,923 | 16,47,10,523 | 16,47,51,723 | 16,47,51,723 | 16,47,51,723 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,47,56,423 | 16,49,59,682 | 16,50,10,854 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. Shares locked in in the glossary | 11,40,85,855 | 11,43,95,955 | 11,40,85,855 | 11,40,85,855 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Promoters' shares locked in | 9,52,93,934 | 9,52,93,934 | 9,52,93,934 | 9,52,93,934 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 3,26,56,565 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
Gland Pharma promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Fosun Pharma Industrial Pte. Ltd, 45.75%.Promoter buying and selling
| Holder | ||
|---|---|---|
| Fosun Pharma Industrial Pte. LtdForeign companies and others | 45.75% | 7,54,96,894 |
| Regal Gesture LimitedForeign companies and others | 0.00% | 10 |
| Lustrous Star LimitedForeign companies and others | 0.00% | 10 |
| Fosun Industrial Co LimitedForeign companies and others | 0.00% | 10 |
| Ample Up LimitedForeign companies and others | 0.00% | 10 |
Largest public holders of Gland Pharma, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Gland Pharma
| Holder | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hdfc Life Insurance Company LimitedInsurance companies | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.51% |
| Government Pension Fund GlobalForeign portfolio investors, category I | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 1.42% | 1.49% | 1.34% | 1.36% | 1.36% | 1.34% | 1.32% |
| Rp Advisory Services Private LimitedCompanies | 3.78% | 3.77% | – | 3.75% | – | – | – | – | – | – | – | – | 3.74% | 3.74% | – | – | – | – | – | – | – | – | – | – |
| Nicomac Machinery Private LimitedCompanies | – | – | – | – | – | 5.81% | 1.93% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | 1.19% | – | – | – | – | – | – | – | – | – | – |
| R P Advisory Services Private Limited-Trustee of Empower Discretionary TrustCompanies | – | – | 2.62% | – | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | 2.61% | – | – | – | – | – | – | – | – | – | – | – | – |
| R P Advisory Services Private Limited-Trustee of Nilay Discretionary TrustCompanies | – | – | 1.14% | – | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | 1.14% | – | – | – | – | – | – | – | – | – | – | – | – |
| Government of SingaporeInstitutions Foreign Portfolio Investor | 2.66% | 2.23% | 1.54% | 1.21% | 1.11% | – | 1.05% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| New World Fund IncInstitutions Foreign Portfolio Investor | – | – | – | 1.27% | 1.27% | 1.27% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Gland Celsus Bio Chemicals Private LimitedOther non-institutions | 6.15% | 6.14% | 6.13% | 6.12% | 6.12% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Smallcap World Fund, IncInstitutions Foreign Portfolio Investor | 1.21% | 1.20% | 1.20% | 1.20% | 1.20% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
Who moved in the Sep 2026 filing
Against the Jun 2026 filing. A filing names a public holder only at 1% or more, so a holder no longer named fell under 1% or sold out.
- Foreign institutions: Government Pension Fund Global 1.32%, −0.02 pts
- Indian institutions: Hdfc Life Insurance Company Limited newly named at 1.51%